comparemela.com

Latest Breaking News On - Dapagliflozin - Page 4 : comparemela.com

Use of SGLT2 inhibitors tied to lower dementia risk in older people with type 2 diabetes: Study

Canada: The new use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase 4 (DPP-4) inhibitors confers 20% lower dementia risk in older people with type 2 diabetes, a.

AstraZeneca Pharma India receives permission for Dapagliflozin tablets

AstraZeneca Pharma India Ltd has received an Import and Market permission in Form CT-20 from the CDSCO , Directorate General of Health Services, Government of India for Dapagliflozin i.e., Forxiga® tablets of 10 mg - additional indication.

SGLT2 Inhibitors: An Evolution in Diabetes Mellitus?

Glenmark launches Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

Glenmark Pharmaceuticals Ltd became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities.

Alkem launches first time in India FDC of Dapagliflozin, Sitagliptin and Metformin for adults with Type 2 diabetes in India

Mumbai (Maharashtra) [India], October 6 (ANI/PRNewswire): Alkem Laboratories Limited, the 5th largest Indian pharmaceutical company, has launched for the first time in India, triple drug fixed dose combination (FDC) of Dapagliflozin, Sitagliptin and Metformin under the brand name of Dapanorm Trio at an affordable price for adults with Type 2 Diabetes in India.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.